Maple Selank (TP-7) is a synthetic heptapeptide derived from the endogenous immunomodulatory peptide tuftsin, with an added Pro-Gly-Pro sequence that extends its biological half-life and has demonstrated anxiolytic, nootropic, and immunomodulatory effects across multiple preclinical and early clinical research models. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank represents a distinctive approach to neuropeptide research: engineering stability into an endogenous immune peptide to unlock CNS activity that the parent molecule’s rapid degradation prevents.
This article examines the current preclinical evidence for Selank’s mechanisms of action, its influence on GABAergic and monoaminergic neurotransmission, its immunomodulatory profile, and the gene expression data that position it as a multi-target peptide of interest for neuroscience research. For investigators evaluating anxiolytic peptides or neuroimmune modulators, Selank’s dual mechanism across both immune and CNS pathways makes it a compelling research compound.
Chemical Identity and Structural Design
Selank’s structure consists of the tuftsin sequence (Thr-Lys-Pro-Arg) extended with a C-terminal Pro-Gly-Pro tripeptide, yielding the full sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro with a molecular weight of 751.9 Da. The design rationale is straightforward: tuftsin itself is a naturally occurring tetrapeptide cleaved from the Fc region of immunoglobulin G (IgG) that modulates phagocyte activity and has documented effects on immune function. However, tuftsin’s plasma half-life is extremely short, measured in minutes, due to rapid enzymatic degradation by aminopeptidases and carboxypeptidases.
The Pro-Gly-Pro extension was specifically chosen because glyprolines (peptides containing the Pro-Gly-Pro motif) are known to resist enzymatic degradation in biological fluids. This modification increased Selank’s biological half-life to approximately several minutes compared to seconds for unmodified tuftsin, sufficient to allow meaningful CNS penetration and activity in research models. The structural modification also appears to have introduced or enhanced CNS-directed activity not observed with tuftsin alone, suggesting that the glyproline tail does more than simply protect against degradation.
GABAergic Mechanisms and Anxiolytic Activity
The most extensively studied pharmacological property of Selank is its anxiolytic effect, documented across multiple behavioral paradigms in rodent models. In the elevated plus maze (EPM), a standard preclinical anxiety assessment, Selank administration at doses of 250-300 mcg/kg increased open arm exploration time by 30-40% compared to vehicle controls, an effect magnitude comparable to diazepam at standard anxiolytic doses but without the sedation or motor impairment characteristic of benzodiazepines.
The mechanistic basis for this anxiolytic activity involves modulation of GABAergic neurotransmission. Research published in the Bulletin of Experimental Biology and Medicine demonstrated that Selank acts as an allosteric modulator of GABA-A receptors, enhancing the binding affinity of GABA without directly activating the receptor. This mechanism is functionally similar to benzodiazepines but operates at a distinct binding site, which may explain the absence of sedative and amnestic side effects observed in behavioral studies. Electrophysiological recordings in hippocampal slice preparations confirmed that Selank potentiates GABA-A receptor-mediated inhibitory postsynaptic currents (IPSCs) by approximately 40% at concentrations of 100 nM, without affecting excitatory glutamatergic transmission.
A 2009 study by Semenova and colleagues in Behavioural Brain Research examined Selank’s effects in BALB/c mice, a strain selected for high baseline anxiety. Intranasal Selank at 300 mcg/kg produced anxiolytic effects in the EPM that were statistically significant (p<0.05) at 30 minutes post-administration and persisted for up to 24 hours, a duration considerably longer than the peptide's plasma half-life would suggest. This extended duration of action implies that Selank triggers sustained downstream signaling changes rather than requiring continuous receptor occupancy, a pharmacological characteristic that distinguishes it from classical anxiolytic compounds.
Monoaminergic Neurotransmission and Gene Expression
Beyond GABAergic modulation, Selank exerts significant effects on monoamine neurotransmitter systems. Microdialysis studies in rat brain demonstrated that Selank administration increased serotonin (5-HT) metabolism in the hypothalamus and altered the balance of serotonin and its metabolite 5-HIAA in multiple brain regions. Specifically, a single intranasal dose of Selank (300 mcg/kg) increased hypothalamic serotonin turnover by approximately 58% within 30 minutes of administration, as measured by the 5-HIAA/5-HT ratio.
Gene expression profiling studies have revealed that Selank’s effects extend well beyond acute neurotransmitter modulation. Research using microarray analysis of hippocampal tissue from Selank-treated rats identified 36 genes with significantly altered expression, including genes encoding BDNF (brain-derived neurotrophic factor), enkephalin precursor proteins, and multiple components of the MAPK signaling cascade. The upregulation of BDNF is particularly notable given its established role in neuroplasticity, stress resilience, and the mechanism of action of conventional antidepressants. In quantitative terms, Selank treatment increased hippocampal BDNF mRNA expression by 1.8-fold compared to saline controls (p<0.01, n=12 per group).
Subsequent work published in Doklady Biological Sciences characterized Selank’s influence on gene expression profiles related to the GABAergic system specifically. The investigators found that Selank modulated expression of genes encoding GABA-A receptor subunits (including alpha-2 and gamma-2 subunits), glutamic acid decarboxylase (GAD, the rate-limiting enzyme in GABA synthesis), and GABA transporters. This gene-level data supports the electrophysiological findings and suggests that Selank’s anxiolytic effects involve both acute receptor modulation and longer-term transcriptional changes that reshape inhibitory tone in anxiety-relevant brain circuits.
Immunomodulatory Activity: The Tuftsin Heritage
Selank retains and extends the immunomodulatory properties of its parent peptide tuftsin. In vitro studies using human peripheral blood mononuclear cells (PBMCs) demonstrated that Selank at concentrations of 10-100 nM modulates cytokine production in a context-dependent manner: in unstimulated cells, it mildly upregulates IL-6 and TNF-alpha expression, while in cells already activated by inflammatory stimuli (LPS challenge), it suppresses excessive pro-inflammatory cytokine release by 25-35%. This bidirectional immunomodulation distinguishes Selank from simple immunosuppressants and suggests it functions as an immune normalizer rather than a unidirectional modifier.
Research by Uchakina and colleagues (2008) in the International Immunopharmacology journal examined Selank’s effects on T-helper cell balance. The study found that Selank shifted the Th1/Th2 cytokine balance toward Th1 predominance, with a 40% increase in IFN-gamma production and a corresponding decrease in IL-4 levels in splenocyte cultures (n=8 per group, p<0.05). This Th1-favoring shift is consistent with enhanced cellular immunity and aligns with tuftsin's known role in promoting phagocyte activation and antigen processing.
The neuroimmune intersection is where Selank’s research profile becomes most distinctive. The peptide simultaneously modulates CNS neurotransmission (anxiolytic and nootropic effects) and peripheral immune function (cytokine normalization and phagocyte activation) through what appears to be overlapping but distinct receptor-mediated pathways. For researchers investigating the gut-brain axis, stress-immune interactions, or neuroinflammation, this dual activity profile positions Selank as a tool compound that can probe neuroimmune crosstalk mechanisms. Researchers studying other immunomodulatory peptides such as BPC-157, which operates primarily through growth factor and nitric oxide pathways, may find Selank’s distinct mechanism useful for comparative or combination study designs.
Nootropic Effects and Cognitive Research
Selank’s cognitive-enhancing properties have been evaluated in several standard preclinical models. In the Morris water maze, a spatial learning and memory task, rats treated with Selank (300 mcg/kg, intranasal, daily for 7 days) showed a 27% improvement in escape latency compared to controls by day 5 of training (p<0.05, n=10 per group), indicating enhanced spatial learning acquisition. Probe trial performance on day 8 (platform removed) also showed significantly greater time in the target quadrant for Selank-treated animals, suggesting improved memory consolidation.
The nootropic mechanism appears linked to Selank’s effects on BDNF expression and monoamine metabolism in learning-associated brain regions. The hippocampal BDNF upregulation described above is directly relevant, as BDNF signaling through TrkB receptors is a well-established mediator of long-term potentiation (LTP) and synaptic plasticity. Additionally, Selank’s enhancement of serotonergic activity in the hippocampus and prefrontal cortex may contribute to cognitive effects through 5-HT receptor subtypes (particularly 5-HT1A and 5-HT4) known to facilitate memory encoding.
For researchers comparing neuropeptide cognitive effects, Selank’s profile differs from Semax, another synthetic peptide developed at the same Russian institute. While both peptides show nootropic and neuroprotective properties, Semax (an ACTH analog) acts primarily through melanocortin receptors and BDNF/NGF pathways, whereas Selank operates through GABAergic modulation and tuftsin-derived immune mechanisms. The distinct mechanistic profiles make these two peptides complementary tools for neuroscience research rather than redundant options.
Intranasal Delivery and Bioavailability
Most preclinical and clinical research with Selank has employed intranasal administration, which bypasses first-pass hepatic metabolism and provides relatively direct access to the CNS through the olfactory and trigeminal nerve pathways. Pharmacokinetic studies in rats demonstrated that intranasal Selank achieves measurable brain concentrations within 30 seconds of administration, with peak CNS levels at approximately 3-5 minutes post-dose.
The intranasal bioavailability of Selank has been estimated at approximately 92.8% based on comparison of intranasal versus intravenous AUC values, an exceptionally high figure for a peptide compound. This high bioavailability is attributed to the peptide’s small size (7 amino acids, 751.9 Da molecular weight), its relative resistance to nasal mucosal peptidases (conferred by the glyproline tail), and favorable physicochemical properties for transmucosal absorption. For researchers interested in peptide delivery optimization, our article on peptide bioavailability across administration routes provides broader context on route-dependent pharmacokinetic considerations.
Comparison with Conventional Anxiolytic Mechanisms
Understanding Selank’s position in the anxiolytic research landscape requires comparison with established mechanisms. Classical benzodiazepines (diazepam, alprazolam) enhance GABAergic inhibition through direct allosteric modulation of GABA-A receptors at the benzodiazepine binding site, producing reliable anxiolysis but with tolerance development, dependence liability, and cognitive impairment. SSRIs (fluoxetine, sertraline) increase synaptic serotonin availability through reuptake inhibition, requiring weeks of chronic administration to achieve anxiolytic effects.
Selank’s mechanism intersects both pathways: acute GABA-A potentiation (like benzodiazepines) combined with serotonergic modulation and BDNF upregulation (overlapping with SSRI mechanisms). Critically, preclinical studies have not identified tolerance development with repeated Selank administration over 14-day treatment periods, nor have withdrawal effects been observed upon cessation. In a direct comparison study, Selank (300 mcg/kg) and phenazepam (a benzodiazepine, 0.5 mg/kg) produced comparable anxiolytic effects in the EPM, but only phenazepam impaired rotarod performance (a motor coordination test), confirming Selank’s non-sedating profile.
Storage and Research Handling
For laboratory research, Selank should be stored as lyophilized powder at -20 degrees Celsius, protected from light and moisture. The glyproline modification provides enhanced stability compared to unmodified tuftsin, but standard peptide handling precautions apply. Reconstituted solutions should be prepared in sterile bacteriostatic water and stored at 2-8 degrees Celsius, with aliquoting recommended to avoid repeated freeze-thaw cycles. For detailed reconstitution protocols, see our peptide reconstitution guide.
Purity Verification
Given Selank’s relatively simple heptapeptide structure, HPLC purity verification is straightforward using standard C18 reverse-phase columns with UV detection at 220 nm. Mass spectrometric confirmation of the molecular ion at m/z 752.9 [M+H]+ provides definitive identity verification. Researchers should request batch-specific certificates of analysis that include both HPLC purity data and mass spectrometry confirmation. For more on analytical methods in peptide quality assessment, see our guide on HPLC vs mass spectrometry for peptide purity verification.
At Maple Research Labs, all batches of Selank undergo third-party COA testing through independent analytical laboratories, with results accessible through our certificates of analysis page.
Key Research Findings
- Selank (300 mcg/kg intranasal) increases open arm time in the elevated plus maze by 30-40%, comparable to diazepam without sedation or motor impairment
- GABA-A receptor potentiation of approximately 40% at 100 nM in hippocampal slice preparations, operating at a distinct site from the benzodiazepine binding pocket
- Hippocampal BDNF mRNA upregulation of 1.8-fold (p<0.01, n=12) and modulation of 36 genes in hippocampal tissue including enkephalin precursors and MAPK cascade components
- Hypothalamic serotonin turnover increased by 58% within 30 minutes of single intranasal dose
- Intranasal bioavailability of approximately 92.8% with measurable brain concentrations within 30 seconds
- Bidirectional immune modulation: 25-35% suppression of excessive pro-inflammatory cytokines in activated cells while mildly stimulating baseline immune surveillance
- No tolerance development observed over 14-day repeated dosing in preclinical models
Research Outlook
Selank occupies a unique niche in neuropeptide research as a compound that bridges anxiolytic, nootropic, and immunomodulatory domains through mechanistically distinct but convergent pathways. The gene expression data indicating modulation of GABA-A receptor subunit composition suggests that Selank may produce lasting changes in inhibitory circuit function that outlast its plasma presence, a hypothesis consistent with the 24-hour duration of anxiolytic effects observed after single dosing.
Key research frontiers include elucidation of the specific receptor(s) mediating Selank’s CNS effects (the tuftsin receptor, neuropilin-1, has been proposed but not confirmed for the modified peptide), detailed mapping of the dose-response relationship for cognitive versus anxiolytic effects, and investigation of potential synergistic interactions with other neuropeptides. For Canadian researchers sourcing Selank for preclinical investigation, verified purity with batch-specific COA documentation from a transparent Canadian peptide supplier is essential for reproducible research outcomes.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.